Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/29/2026

1. LFTO
2. CMCSA
3. QNT
4. VRDN
5. NVDA
6. INIO
7. HONA
8. ABBV
9. HON
10. SPY

Go back to Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results
(NASDAQ: DNTH) Delayed: 95.68 +0.33 (0.35%)
Previous Close $95.35    52 Week High $ 
Open $96.05    52 Week Low $ 
Day High $97.38    P/E N/A 
Day Low $92.47    EPS $ 
Volume 1,349,909